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Abstract
 
Transcription factor GATA-1 reprograms immature myeloid cells to three different hemato-
poietic lineages-erythroid cells, megakaryocytes, and eosinophils. GATA-1 is essential for mat-
uration of erythroid and megakaryocytic precursors, as revealed by gene targeting in mice.
Here we demonstrate that deletion of a high-affinity GATA-binding site in the GATA-1 pro-
moter, an element presumed to mediate positive autoregulation of GATA-1 expression, leads
to selective loss of the eosinophil lineage. These findings suggest that GATA-1 is required for
specification of this lineage during hematopoietic development. Mice lacking the ability to
produce eosinophils should prove useful in ascertaining the role of eosinophils in a variety of
inflammatory or allergic disorders.
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Introduction
 
Transcription factor GATA-1 is expressed in four hemato-
poietic lineages-erythroid cells, megakaryocytes, mast cells,
 
and eosinophils-and is competent to reprogram 
 
myb/ets-
 
transformed chicken myelomonocytic cells into three of
these (erythroid, megakaryocytic, and eosinophilic) (1). In-
termediate levels of GATA-1 protein lead to formation of
eosinophils, and higher levels to thromboblasts and proba-
 
bly erythroblasts. Gene targeting in mice has revealed essen-
tial roles for GATA-1 in both erythroid and megakaryo-
cytic differentiation. In both contexts, the loss of GATA-1
arrests cellular maturation at a relatively late stage after lin-
eage commitment. Overlapping expression of the related
factor GATA-2 very likely accounts for lineage commit-
ment in the absence of GATA-1. The extent to which
GATA-1 is required for eosinophil or mast cell develop-
ment or function is unresolved.
Transcription of the GATA-1 gene itself is directed by
several cis-regulatory elements. In the sole nonhematopoi-
etic site of expression an upstream promoter (IT) of murine
GATA-1 directs Sertoli-cell specific expression (2). He-
matopoietic cells express GATA-1 predominantly from a
downstream promoter (IE) and exhibit heterogeneous
transcriptional start sites (3–7). At least two DNase I hyper-
sensitive regions neighboring, or upstream of, the IE pro-
moter have been identified in hematopoietic cells. The
more distal region (termed HSI) is hypersensitive in both
erythroid and megakaryocytic cells and encompasses a po-
tent enhancer core of 169 bp that is able to direct expres-
sion in these lineages in transgenic mice (8, 9). Deletion of
HSI in the native chromosomal context by gene targeting
ablates expression of GATA-1 in megakaryocytes (10). The
expression of GATA-1 in erythroid cells is maintained,
presumably due to compensatory cis-elements located else-
where within the GATA-1 locus.
Other sequences neighboring the IE promoter also ex-
hibit DNase I hypersensitivity in erythroid cells. In vivo
DNA footprinting has revealed protein occupancy in a
high affinity palindromic (or “double”) GATA-site posi-
tioned 500-bp upstream of the heterogeneous start sites (6).
This complex GATA-site binds a single molecule of
 
GATA-1 with an affinity 
 
 
 
7 times that of a single GATA
site (6, 11). In transient transactivation reporter assays the
palindromic GATA-site is required for full promoter activ-
ity. Chromatin-immunoprecipitation (CHIP) assay dem-
onstrates direct binding of GATA-1 protein to this site in
cultured erythroid cells (unpublished data). It has been pro-
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posed that the palindromic GATA-site in the GATA-1
promoter mediates positive autoregulation of GATA-1
transcription by GATA-1 itself, and thereby ensures ex-
pression of the gene once activated (6). Indeed, transgenic
experiments in zebrafish have shown that GATA-1 expres-
sion is dependent on a similar palindromic site in the ze-
brafish gene promoter and have been interpreted as support
for this hypothesis (12).
In the studies reported here we sought to determine the
in vivo relevance of the palindromic GATA-site by modi-
fying the endogenous GATA-1 locus in mice. Remark-
ably, mice harboring a deletion of the double GATA-site
 
(
 
 
 
dblGATA) are unable to produce eosinophils. Unlike
GATA-1-null mice, which die in utero with profound
anemia and defective megakaryocyte development, 
 
 
 
dbl-
GATA mice are viable and fertile. Platelet and mast cell de-
velopment appear normal, while red cell production is only
subtly impaired. Thus, the double GATA-site is not re-
quired for activation or maintenance of GATA-1 expres-
sion in erythroid cells, megakaryocytes, mast cells, or earlier
hematopoietic precursors, but is necessary for eosinophil
development. Taken together with evidence that GATA-1
can reprogram myeloid cells to eosinophils, our findings
suggest that GATA-1 is required for specification of the
eosinophil lineage.
 
Materials and Methods
 
Gene Targeting of the Murine GATA-1 Locus.
 
Homologous
recombination was used to replace a 21-bp region comprising the
double-GATA site upstream of the last nucleotide of the first he-
matopoietic exon (IE) of the murine GATA-1 gene. Two frag-
ments of the GATA-1 locus were amplified by PCR with the
 
following primer pairs: DGU53, 5
 
 
 
-TTATGGATCCAAGGAA-
GAGAGGACATTAGCAT-3
 
 
 
 and DGU35, 5
 
 
 
-TATCAGCG-
GCCGCGGACTCGACTGTGGCTGTTGGT-3
 
 
 
; DGD53,
 
5
 
 
 
-TCACCAGCGGCCGCCCCAGAGCAGGCCAGAGC-3
 
 
 
and DGD35, 5
 
 
 
-TTGTGTCGACCAGCCCTCACCCCAGG-
TAACT-3
 
 
 
. These products were cloned into pBlueScript (Strat-
agene), and a floxed PGK-neo cassette was introduced into the
deleted site. The construct was linearized with PvuI and elec-
troporated into CJ7 ES cells as described previously (13). The
PGK-neo cassette was removed after electroporation of a vector
expressing the cre recombinase. In the resulting mutant allele the
double GATA-site is replaced by a single loxP site flanked by two
NotI sites.
Wild-type (wt) and mutant alleles were distinguished by PCR
with the following primers: G1mutF1, 5
 
 
 
-CCCAATCCTCTG-
GACTCCCA-3
 
 
 
, and G1mutR, 5
 
 
 
-CCTACTGTGTACCAG-
 
GCTAT-3
 
 
 
, which yielded a 459-bp product from wt and a 509-bp
product from mutant. Further genotype confirmation was per-
formed by digestion of these PCR products with NotI; this di-
gestion cleaves only the mutant PCR product to yield fragments
of 300 and 200 bp.
 
Hematologic Evaluations.
 
200–500 
 
 
 
l of blood from adult mice
were collected in EDTA-coated tubes (Becton Dickinson) and
analyzed on a Bayer ADVIA 120 Hematology System by the
Clinical Laboratories of Children’s Hospital (Boston, MA). Man-
ual leukocyte differential counts of 
 
 
 
300 cells per sample were
performed on Wright-Giemsa–stained blood smears. Cytocentri-
fuge preparations of the bone marrow and spleens of adult mice
were also stained with Wright-Giemsa for microscopic evaluation.
 
Transgenic Mice Expressing IL-5.
 
Mice heterozygous for a
transgene that expresses murine IL-5 under the control of human
CD2 regulatory sequences (14) were provided by Alison Hum-
bles and Craig Gerard (Children’s Hospital). The presence of the
hCD2-mIL-5 transgene was verified by PCR with a forward
primer from human CD2 (C1F1, 5
 
 
 
-ACCCATGTAGAG-
GCAACAGC-3
 
 
 
) and a reverse primer from murine IL-5 cDNA
(C1R1, 5
 
 
 
-CTACCGGTGCAAAGTGTGTG-3
 
 
 
), which yield
a 585-bp product.
 
RT-PCR Analysis of Bone Marrow Gene Expression.
 
Bone
marrow was harvested from femurs of 6-mo-old wt or hemizy-
gous 
 
 
 
dblGATA mutant male mice. Total RNA was prepared
with the Trizol reagent (LifeTech) according to the manufac-
turer’s instructions. Complementary DNA was created with the
SuperScript II RT (LifeTech) according to the manufacturer’s in-
structions. PCR was subsequently performed with the following
primer pairs (all listed with 5
 
 
 
 end first), yielding products of the
indicated sizes. CD11b: CD11BF1, GACCCAGGTTACCGT-
CTACTAC, and CD11BR1, TTCAGCACTGGGGTCCTTT-
CAAGC, 622 bp; CD34: CD34F1, GGGTATCTGCCTGGA-
ACTAAG, and CD34R1, TTGCCCACCCAACCAAATCAC,
614 bp; myeloperoxidase: MPOF1, ATGCAGTGGGGACAG-
TTTCTG, and MPOR1, GTCGTTGTAGGATCGGTACTG,
695 bp; G-CSF receptor: GCSFRF1, CTCAAACCTATCCT-
GCCTCATG, and GCSFRR1, TCCAGGCAGAGATGAGC-
GAATG, 573 bp; PU.1: PU1F1, GAGTTTGAGAACTTC-
CCTGAG, and PU1R1, TGGTAGGTCATCTTCTTGCGG,
500 bp. Eosinophil peroxidase: EPXF1, CCTTTTGACAAC-
CTGCATGA, and EPXR1, CCCAGATGTCAATGTTGTCG,
799 bp; eosinophil major basic protein 1: MBP1F1, GGAGC-
GTCTGCTCTTCATCT, and MBP1R1, ACTTCCATCAAC-
CCATCGAA, 501 bp; CCR3: CCR3F1, TCCTGCCTCCAC-
 
TGTACTCC, and CCR3R1, CGTGCTGTGAAAAGCAGAAA,
695 bp. Previously described primers were used to identify gly-
coprotein Ib (15) and von Willebrand factor (16). Erythropoie-
tin receptor: EPORF, GGACACCTACTTGGTATTGG, and
EPORR, GACGTTGTAGGCTGGAGTCC, 452 bp; 
 
 
 
-globin:
ALPHA3, CTTCTGATTCTGACAGACTCAG, and ALPHA4,
GCATGGCCAGAAGGCAAGCC, 494 bp; 
 
 
 
-globin: BETA1,
GCTTCTGACATAGTTGTGTTG, and BETA3, GTGGTAC-
TTGTGAGCCAAGGC, 623 bp.
 
Generation and Analyses of Bone Marrow–derived Mast Cells.
 
Bone marrow was obtained from both femurs of a 6-mo-old
male hemizygous 
 
 
 
dblGATA mutant or a wt male littermate
control. Whole marrow was cultured in IMDM (Sigma-Aldrich)
 
containing 15% FCS (Hyclone), 2 mM glutamine (Sigma-
Aldrich), 100 U/ml penicillin G/streptomycin (Sigma-Aldrich),
20 ng/ml murine recombinant SCF (R&D Systems), and 10 ng/
ml recombinant murine IL-3 (R&D Systems) and passaged every
3–4 d into fresh tissue culture dishes for a total of 7 wk.
After 7 wk of culture, cells were cytocentrifuged and stained
with May-Grünwald-Giemsa following standard procedures. Du-
plicate cytospin preparations were fixed in 100% methanol for 5
min, stained in 1% acidified toluidine blue (Sigma-Aldrich) for 5
min, and rinsed in water.
 
FACS
 
®
 
 analysis for expression of c-kit and the high-affinity
IgE receptor was performed as previously described with few
modifications (17). Briefly, bone marrow–derived mast cells were
 
obtained as described above. Low-affinity IgE and Fc
 
 
 
RII/III
 
 
 
receptors were first blocked by incubating with 10 
 
 
 
g/ml anti-
CD23 B3B4 mAb (BD PharMingen) and 10 
 
 
 
g/ml anti-Fc- 
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RII/III
 
 
 
 2.4G2 mAb (BD PharMingen), respectively, for 15
min at 4
 
 
 
C in DMEM containing 2% FCS. Mouse IgE anti-dini-
trophenol (DNP) mAb (Sigma-Aldrich) was then added to a final
concentration of 5 
 
 
 
g/ml and the cells incubated for 1 h at 4
 
 
 
C.
After washing, biotinylated anti–mouse IgE was added (5 
 
 
 
g/ml,
final concentration) and the cells incubated for 30 min at 4
 
 
 
C.
The cells were washed and incubated with streptavidin-APC (BD
PharMingen; final concentration, 2 
 
 
 
g/ml) and PE-conjugated
anti-CD117 (c-kit) (BD PharMingen; final concentration, 2 
 
 
 
g/
ml) for 30 min at 4
 
 
 
C. The cells were washed and analyzed on a
FACSCalibur™ flow cytometer (Becton Dickinson). Negative
controls were performed using an isotype-matched PE-conju-
gated control antibody (c-kit) and omission of primary IgE anti-
body (IgE receptor).
 
Results and Discussion
 
Targeted Deletion of the Palindromic GATA-Site.
 
Se-
quences at 
 
 
 
691 to 
 
 
 
671 bp upstream of the last nucle-
otide of the first hematopoietic exon (IE) of the GATA-1
gene were deleted as outlined in Fig. 1 A. The targeted and
excised (henceforth 
 
 
 
dblGATA) alleles were distinguished
from the wt GATA-1 allele in mice by PCR with primers
flanking the deleted region and subsequent digestion with
NotI (Fig. 1 B). Mice harboring only the 
 
 
 
dblGATA allele
(i.e., homozygous mutant females and hemizygous mutant
males, since GATA-1 is an X-chromosome gene) were vi-
able and fertile and demonstrated no gross abnormalities.
Test crosses between heterozygous mutant females and
hemizygous mutant males yielded expected ratios of prog-
eny of different genotypes (data not shown).
 
Erythro- and Myelopoiesis of 
 
 
 
dblGATA Mice.
 
Auto-
mated analysis of peripheral blood from adult mice revealed
no significant differences between wt and 
 
 
 
dblGATA mice
with respect to white cell or platelet counts (Table I and
data not shown). Erythroid development, however, was
subtly affected in hemizygous mutant males. Erythrocyte
 
number was diminished by 27% from 9.57 
 
 
 
 0.29 
 
 
 
 10
 
6
 
/
 
 
 
l (mean 
 
 
 
 SEM) in wt to 6.97 
 
 
 
 0.49 
 
 
 
 10
 
6
 
/
 
 
 
l in mu-
tant mice (
 
P
 
 
 
 
 
 0.004), with a reduction in hematocrit from
49.6 
 
 
 
 1.1% (wt) to 37.8 
 
 
 
 3.5% (mutant; 
 
P
 
 
 
 
 
 0.018).
The hemoglobin level was also reduced in proportion to
the reduction in erythrocyte number (14.55 
 
 
 
 0.34 g/dL
in wt to 11.00 
 
 
 
 0.94 g/dL in mutant, 
 
P
 
 
 
 
 
 0.012). Apart
from a small elevation in the reticulocyte count in several
mutant samples, all other red cell parameters appeared nor-
mal. Inspection of peripheral blood smears revealed nor-
 
mocytic, normochromic erythrocytes, and platelets of
normal size (Fig. 2). Modest splenomegaly was observed in
mutant animals (data not shown). Together these observa-
tions are consistent with an appropriate in vivo response to
slight impairment in red cell production.
 
Absence of Eosinophils in 
 
 
 
dblGATA Mice.
 
In consider-
ing other possible effects of the targeted mutation on he-
matopoiesis, we examined the production of cells of the
other lineages in which GATA-1 is expressed. Eosinophils
are present in low numbers in normal mice. Manual differ-
ential counts of eosinophil numbers in blood smears were
performed by a blinded observer. As shown in Table I,
eosinophils were absent in homozygous 
 
 
 
dblGATA fe-
males and 
 
 
 
dblGATA mutant males, whereas they com-
Figure 1. Targeting of the GATA-1 locus.
(A, top) The murine GATA-1 locus contains
a double GATA-site upstream of the hemato-
poietic exon IE. Other exons are designated
with Roman numerals, including testis exon
IT. The double-stranded sequence at the as-
terisked region is given below the schematic,
with nucleotides to be deleted marked in
boldface type. (Middle) After targeting, the
double GATA-site is deleted, replaced by a
floxed PGK-neo cassette. (Bottom) After cre
recombinase-mediated excision, the “excised
locus” has a minimal sequence consisting pri-
marily of a single loxP site surrounded by two
Not I sites. N, Not I site. The double-
stranded sequence at the asterisked region is
given below the schematic. (B) PCR geno-
typing of male mice carrying the wt or  dbl-
GATA mutant (hem) allele. PCR products
before (–) and after (N) digestion with Not I. 
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prised 1–2% of nucleated cells in the peripheral blood of
controls.
To assess more stringently the potential of 
 
 
 
dblGATA
 
mice to produce eosinophils, we introduced an IL-5–express-
 
ing transgene into wt and mutant backgrounds. The
IL-5 transgenic mice we employed express a murine IL-5
cDNA under the control of human CD2 regulatory se-
quences. In this context, T-lymphocytes constitutively ex-
press IL-5. Prolonged release of IL-5 leads to chronic eo-
sinophilia, resembling that seen in mice after inoculation
with helminthic parasites (14). The hematological effects of
IL-5 expression are shown in Table II. Eosinophil numbers
were increased in wild-type or heterozygous 
 
 
 
dblGATA
female mice with the transgene. Nonetheless, eosinophils
were absent in hemizygous male 
 
 
 
dblGATA mice. Hence,
even under strenuous cytokine stimulation of eosinophil
production, 
 
 
 
dblGATA mice are unable to produce iden-
tifiable eosinophils.
These morphological observations were confirmed by
automated leukocyte differential analysis (Fig. 3 A–D). Fig.
3 B demonstrates a profile of a female heterozygous for the
 
 
 
dblGATA allele but lacking the IL-5 transgene. Fig. 3 C
shows a marked increase in both the number of eosinophils
and the number of “large unclassified cells” (LUC) in wild-
type male mice with the IL-5 transgene. In Fig. 3 D, an in-
crease in LUC but the absence of eosinophils is evident in a
male hemizygous for the 
 
 
 
dblGATA allele with the IL-5
transgene. Flow cytometric analysis of cell surface markers
 
Table I.
 
Hematologic Parameters in wt and 
 
 
 
dblGATA Mice
 
Sex dblGATA Genotype WBC RBC HGB HCT MCV PLT MPV Manual EO
 
10
 
3
 
/
 
 
 
l1 0
 
6
 
/
 
 
 
l g/dL % fL 10
 
3
 
/
 
 
 
lf L %
 
F
 
het
 
6.60 8.75 14.0 44.5 50.9 1885 14.6 1–2
F
 
hom
 
4.10 8.25 14.5 44.0 53.6 1090 21.7
 
0
 
F
 
hom
 
8.20 8.25 14.0 44.5 54.1 1635 16.5 0
M wt 5.60 8.95 14.5 44.0 49.2 1460 21.7 1–2
M wt 12.65 9.50 14.5 45.0 47.6 2205 17.1 1–2
M hem 7.50 7.30 11.0 36.0 49.0 1950 15.9 0
M hem 8.15 8.15 13.5 43.5 53.2 1095 18.3 0
Automated measurement of blood from adult wt and  dblGATA mutant mouse littermates from a cross between heterozygous mutant female and a
hemizygous mutant male. The dblGATA genotype is designated as follows: het, heterozygous ( dblGATA/ ) mutant female; hom, homozygous
( dblGATA/ dblGATA) mutant female; wt, wild-type ( /Y) male; and hem, hemizygous ( dblGATA/Y) mutant male. Eosinophils are not
observed in homozygous  dblGATA mutant females or hemizygous  dblGATA mutant males. HCT, hematocrit; HGB, hemoglobin concentration;
MCV, mean corpuscular volume; MPV, mean platelet volume; manual EO, manual differential count of eosinophils by a blinded observer; PLT;
platelet count; RBC, erythrocyte count; WBC, leukocyte count.
Figure 2. Peripheral blood from a wt male and a  dblGATA mutant male mouse. Wright-Giemsa staining of blood smears from a wild-type male (A)
and hemizygous  dblGATA mutant (B) male. Red cells and platelets appear normal in the  dblGATA mutant male. Original magnification: 1,000 .1391 Yu et al.
on LUC from both wt and hemizygous  dblGATA mice
showed that these are predominantly B cells, which, like
eosinophils and basophils, express the IL-5 receptor   chain
(reference 18 and data not shown).
Finally, Wright-Giemsa staining of bone marrow from
IL-5 transgenic mice revealed an abundance of eosinophils
in a male with a wt GATA-1 allele (Fig. 3 E); no eosino-
phils are seen in the bone marrow of hemizygous  dbl-
GATA mutant male (Fig. 3 F). Examination of splenocytes
reveals similar findings (data not shown). Together these
findings illustrate that eosinophils are not produced in
 dblGATA mutant mice, even under conditions that nor-
mally stimulate eosinophilia.
If the targeted deletion of the double GATA-site impairs
activation or maintenance of GATA-1 expression necessary
for eosinophil specification, one would anticipate that loss
of GATA-1 through conventional gene targeting would
also prevent eosinophil development. Because GATA-1 
embryos die at E10–11 due to profound anemia (13), we
resorted to analysis of heterozygous female GATA-1 / 
mice. Bone marrow cells of wt and heterozygous mice
were cultured in media containing IL-5 with or without
G418. As the targeted GATA-1 allele contains a neomy-
cin-resistance gene, growth in G418 reflects selection for
Table II. Hematologic Parameters in wt and  dblGATA Mice 
With or Without an IL-5 Transgene
Sex dblGATA Genotype IL-5 Tg WBC Manual EO
103/ l%
F het   5.76 1
F het   43.34 3
F het   24.83 10
Mw t   29.4 10
Mw t   75.69 9
M hem   8.31 0
M hem   50.35 0
M hem   46.65 0
Automated measurement of blood from adult wt and  dblGATA
mutant mouse littermates from a cross between heterozygous
 dblGATA mutant female and a male heterozygous for an IL-5
transgene (see text for details). For an explanation of abbreviations, see
Table I. The IL-5 transgene stimulates eosinophilia in heterozygous
females and wt males but not in male mice hemizygous for the
 dblGATA mutant allele. Manual EO, manual differential count of
eosinophils by a blinded observer; WBC, leukocyte count.
Figure 3. Eosinophilia stimu-
lated by an IL-5 transgene is not
observed in  dblGATA mutant
mice. (A) Schematic of cell pop-
ulations in automated differential
analysis of mouse blood. A het-
erozygous   dblGATA mutant
female displays a normal-appear-
ing differential plot (B). The IL-5
transgene imparts an increase in
the number of eosinophils and
large unclassified cells (C) in a
male with a wt GATA-1 locus.
This increase is not observed in a
hemizygous  dblGATA mutant
male harboring the same trans-
gene (D). (E and F) Wright-
Giemsa staining of bone marrow
from mice harboring the IL-5
transgene. Numerous eosinophils
with bright red granules are evi-
dent in a mouse with a wt
GATA-1 locus (E) but not in a
hemizygous  dblGATA mutant
male (F). Original magnification:
600 .1392 GATA-1 Requirement for Eosinophil Development
precursor cells in which the GATA-1  allele is not X-inac-
tivated. Eosinophils were observed in IL-5–containing cul-
tures only in the absence of G418, whereas control cultures
in IL-3 and G418 yielded viable myeloid cells (data not
shown). These results independently confirm a require-
ment of GATA-1 in eosinophil formation.
Loss of Eosinophil-specific Transcripts in  dblGATA Mice.
We examined the expression of a variety of hematopoietic-
marker RNA transcripts in bone marrow cells by RT-
PCR (Fig. 4). Expression of myeloid (CD11b, CD34,
myeloperoxidase, granulocyte colony stimulating factor re-
ceptor, PU.1), erythroid (erythropoietin receptor,  - and
 -globins), and megakaryocyte/platelet markers (platelet gly-
coprotein Ib, von Willebrand factor) was similar between
wild-type and  dblGATA mice, as anticipated from hema-
tological and morphological data. Of note, eosinophil per-
oxidase (EPX) was present in wild-type mice but absent in
 dblGATA mice. Eosinophil major basic protein-1, which
is highly expressed in eosinophils but not restricted to the
lineage, was markedly reduced in mutant mice, where
CCR3 was expressed at low level in both wt and mutant
mice (19, 20). These expression data are consistent with
our cellular and morphological findings regarding the defi-
ciency of eosinophils in  dblGATA mice, and further sug-
gest that eosinophil precursors are also absent.
Mast Cell Production in  dblGATA Mice. To assess mast
cell production in  dblGATA mice, we cultured wt or
hemizygous   dblGATA bone marrow cells in medium
containing stem cell factor and IL-3 to obtain mast cells
(17). Wt and mutant bone marrow-derived populations
behaved similarly. After culture for 7 wk, mast cells were
present in both, as shown by morphology (Fig. 5 A and B),
the presence of toluidine blue staining granules (Fig. 5 C
and D) and flow cytometric analysis (Fig. 5 E and F) for
expression of c-kit and the high-affinity IgE receptor
(Fc RI), a specific marker of mast cells (21). Thus, the
double GATA-site is dispensable for the generation of
bone marrow–derived mast cells.
Implications of Findings for GATA-1 and Eosinophil Devel-
opment. Here we have demonstrated that deletion of a
high-affinity GATA-site in the GATA-1 promoter specifi-
cally ablates eosinophil production, while the development
of the other GATA-1–expressing lineages (erythroid,
megakaryocytic, mast) is unaffected or only subtly per-
turbed. It appears, therefore, that GATA-1 is required in a
nonredundant manner in the early phase of eosinophil de-
velopment, very likely in lineage specification.
Dependence of the eosinophil lineage on GATA-1
shown here is consistent with, and extends, prior evidence
supporting a role for GATA-1 in eosinophil gene expres-
sion and development. Different levels of enforced GATA-1
expression reprogram lineage determination in myb/ets-
transformed chicken myelomonocytic cells (1); intermedi-
ate levels result in eosinophils, and higher levels in throm-
boblasts and probably erythroblasts. The eosinophil-specific
requirement of the double GATA-site, a site with in-
creased affinity for GATA-1 vis-à-vis single consensus
GATA-site, is compatible with the concentration-depen-
dent outcome of reprogramming. Intermediate levels of
GATA-1 would favor occupancy at high-affinity GATA-
sites, while high levels would allow binding at both high-
and low-affinity GATA-sites.
Transcriptional mechanisms using GATA-1, and acting
on the GATA-1 gene itself, differ between erythroid cells
Figure 4. RT-PCR analysis of gene expression in wt and  dblGATA
mutant male mice. RT-PCR analysis was used to examine gene expression
in the bone marrows of hemizygous  dblGATA mutant (n   3) and wt
(n   3) male mice. Control reactions were performed with both wt and
mutant samples with all primer pair combinations, either without RT or
without cDNA template; in all these cases, no PCR product was gener-
ated (data not shown). EPOR, erythropoietin receptor; EPX, eosinophil
peroxidase; GCSRFR, granulocyte colony stimulating factor receptor;
GPIb, glycoprotein Ib; MBP, major basic protein; MPO, myeloperoxi-
dase; vWf, von Willebrand factor.1393 Yu et al.
and eosinophils. In erythroid cells substantial function of
GATA-1 is dependent on the presence of the transcrip-
tional cofactor FOG-1. Moreover, whereas both HSI
upstream of the GATA-1 gene and the double GATA-
site–containing promoter of the gene are highly active in
erythroid transcription in test systems, neither region is
strictly required for GATA-1 expression in the normal
chromosomal context. In eosinophils, on the other hand,
the function of GATA-1 is independent of FOG-1. Indeed,
FOG-1 expression is antagonistic to eosinophil develop-
Figure 5. Production of mast cells from wt and  dblGATA mutant male mice. May-Grünwald-Giemsa (A and B) and toluidine blue stains (C and D)
of cytospin preparations of bone marrow–derived mast cells, from wt (A and C) or  dblGATA mutant (B and D) male mice (original magnification:
1,000 ). Toluidine blue-positive cells contain dark blue cytoplasmic granules. (E and F) Two-color FACS® analysis of c-kit (x-axis) and high-affinity
IgE receptor (y-axis) expression of bone marrow–derived mast cells from wt (E) or  dblGATA mutant (F) male mice. Mast cells are observed in both wt
and mutant mice.1394 GATA-1 Requirement for Eosinophil Development
ment and downregulation of FOG-1 under the aegis of
C/EBP is a prerequisite for eosinophil differentiation to
ensue (22–24). FOG-1 independence of GATA-1 function
in eosinophils may suggest that the NH2-terminal activation
domain of GATA-1, which is not absolutely required for
transcription in erythroid and megakaryocyte lineages, is
likely to be required in eosinophils. In addition, as shown
here, removal of a limited region of the GATA-1 promoter,
that containing the double GATA-site, ablates eosinophil
development, presumably by interfering with activation or
maintenance of GATA-1 expression in this lineage, but
spares erythroid and megakaryocytic development. We
speculate that the double GATA-site serves as a critical
docking site for the assembly of a protein complex contain-
ing GATA-1 and other eosinophil-required transcription
factors, such as C/EBP . As an alternative explanation for
the absence of eosinophils on removal of this site, it could be
suggested that GATA-1 transcripts in eosinophils initiate up-
stream of the start positions employed in erythroid cells. If
this were the case, erythroid and eosinophil GATA-1
mRNAs would differ in size. Arguing against this specula-
tion are Northern blot analyses we have performed on RNA
prepared from eosinophil-enriched populations grown from
bone marrow of wild-type mice harboring the IL-5 trans-
gene. GATA-1 transcripts of erythroid and eosinophil cells
are not distinguishable in size (data not shown).
 dblGATA mice are unique to our knowledge in being
the first mouse strain with a specific deficiency of the eo-
sinophil lineage. These animals should prove useful in the
study of eosinophil function and eosinophil-related pathol-
ogies. It should be possible, for example, to ascertain
whether eosinophils represent a primary etiologic agent or
a secondary inflammatory bystander in the pathogenesis of
asthma or other allergic disorders.
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